Hatice Yucel
Overview
Explore the profile of Hatice Yucel including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
7
Citations
446
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Musiani D, Yucel H, Vallette M, Angrisani A, El Botty R, Ouine B, et al.
Mol Cell
. 2025 Feb;
PMID: 40010343
Resistance to poly (ADP-ribose) polymerase (PARP) inhibitors (PARPis) is the major obstacle to their effectiveness in the treatment of homologous recombination (HR)-deficient (HRD) tumors. Hence, developing alternative treatments for HRD...
2.
Yucel H, Eksi A, Gumussoy S, Ozturk S
Int Emerg Nurs
. 2023 Mar;
68:101270.
PMID: 36924578
Aim: It is aimed to evaluate the knowledge of Pre-Hospital Emergency Health Services (PHEMS) staff about the treat and release criteria in hypoglycemia cases and their attitudes in the decision-making...
3.
Zhou J, Gelot C, Pantelidou C, Li A, Yucel H, Davis R, et al.
Nat Cancer
. 2021 Jun;
2(6):598-610.
PMID: 34179826
DNA polymerase theta (POLθ) is synthetic lethal with Homologous Recombination (HR) deficiency and thus a candidate target for HR-deficient cancers. Through high-throughput small molecule screens we identified the antibiotic Novobiocin...
4.
Borst G, Kumareswaran R, Yucel H, Telli S, Do T, McKee T, et al.
Oncotarget
. 2020 May;
11(17):1573-1574.
PMID: 32391125
[This corrects the article DOI: 10.18632/oncotarget.20936.].
5.
Borst G, Kumareswaran R, Yucel H, Telli S, Do T, McKee T, et al.
Oncotarget
. 2017 Nov;
8(50):87638-87646.
PMID: 29152107
Clinical trials are studying the benefits of combining the PARP-1 inhibitor olaparib with chemotherapy and radiotherapy treatment in a variety of cancer increasing the therapeutic ratio for olaparib may come...
6.
Rondinelli B, Gogola E, Yucel H, Duarte A, van de Ven M, van der Sluijs R, et al.
Nat Cell Biol
. 2017 Oct;
19(11):1371-1378.
PMID: 29035360
The emergence of resistance to poly-ADP-ribose polymerase inhibitors (PARPi) poses a threat to the treatment of BRCA1 and BRCA2 (BRCA1/2)-deficient tumours. Stabilization of stalled DNA replication forks is a recently...
7.
Annunziato S, Kas S, Nethe M, Yucel H, Del Bravo J, Pritchard C, et al.
Genes Dev
. 2016 Jun;
30(12):1470-80.
PMID: 27340177
Large-scale sequencing studies are rapidly identifying putative oncogenic mutations in human tumors. However, discrimination between passenger and driver events in tumorigenesis remains challenging and requires in vivo validation studies in...
8.
Dertlioglu S, Oguz H, Cicek D, Yucel H
Cutis
. 2016 May;
97(4):E21-5.
PMID: 27163923
Vitiligo is an acquired idiopathic disease characterized by depigmented maculae and melanocytic destruction. We determined the prevalence of glaucoma in 49 patients who had presented to the dermatology polyclinic with...